Success examples
Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights

Müller M. R., Burmeister A., Skowron M. A., Stephan A., Bremmer F., Wakileh G. A., Petzsch P., Köhrer K., Albers P., Nettersheim D.

Clin Epigenetics 2022, 14 (1):5.

BET PROTAC
DOI
PubMed
Success examples
Development of cellular metabolite-based MALDI mass spectrometry assays for drug discovery

Weight D.

heiDOK 2019.

FAS inhibitor
DOI
Success examples
The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas

Skowron M. A., Becker T. K., Kurz L., Jostes S., Bremmer F., Fronhoffs F., Funke K., Wakileh G. A., Müller M. R., Burmeister A., Lenz T., Stefanski A., Stühler K., Petzsch P., Köhrer K., Altevogt P., Albers P., Kristiansen G., Schorle H., Nettersheim D.

Mol Oncol. 2022, (4):982-1008.

BET PROTAC
DOI
PubMed
Success examples
ACKR3 promotes CXCL12/CXCR4-mediated cell-to-cell-induced lymphoma migration through LTB4 production

Antonello P., Pizzagalli D. U., Foglierini M., Melgrati S., Radice E., Thelen S., Thelen M.

Front Immunol. 2023, 13:1067885.

LTB4 receptor antagonist
DOI
PubMed
Success examples
Senolytic Flavonoids Enhance Type-I and Type-II Cell Death in Human Radioresistant Colon Cancer Cells through AMPK/MAPK Pathway

Russo M., Moccia St., Luongo D., Russo G. L.

Cancers (Basel) 2023, 15(9):2660.

AMPK Activator
DOI
PubMed
Success examples
Deaminative chlorination of aminoheterocycles

Ghiazza C., Faber T., Gómez-Palomino A., Cornella J.

Nat Chem 2022, (1):78-84.

FLAP antagonist
DOI
PubMed